Skip Navigation Links

Bookmark and Share
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore’s Experimental Drug Development Centre’s 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide
Everest gains exclusive global rights to a series of 3CL protease inhibitors to treat COVID-19 Everest will have sub-licensing rights and full technology transfer Licensing of 3CL prote...

Full "IntellAsia: Resources" article

Disclaimer | Terms Of Use And Privacy Statement

© Metals News. All rights reserved.